Phaseline

Companies › TiumBio

TiumBio: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TU2218–Phase 1Solid Tumor; Advanced Solid TumorDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05784688TU2218Phase 1Solid TumorOncologyDec 2026
NCT05204862TU2218Phase 1Advanced Solid TumorOncologySep 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.